biotech

Welcome to the 'biotech' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'biotech'.

Are you an expert about 'biotech'? Do you want to be the Technorati authority on 'biotech'? You can write a description that will appear right here: Join Blogcritics!

Original Technorati articles tagged “biotech”

• in Business
  Colorado Startup VetDC Targets Biotech Breakthroughs for Pets
  Colorado State University Spinoff Signs Licensing Deal for Cancer Drug
  by johnjegan / on Mar 16, 2011
• in Business
  Pharmaceutical Stocks Expected to Skyrocket in 2011
  2011 pharmaceutical stocks to take a look at.
  by caroline1234 / on Jan 25, 2011
• in Family
  FDA Logic Provides Another Reason To Choose Wild-Caught Salmon
  The FDA is on the verge of approving genetically modified salmon, but wont require GM labeling AND will not allow non-modified salmon to be labeled as such
  by terrasanoblog / on Sep 21, 2010

Latest blogosphere posts tagged “biotech”

 

• Science Panel Recommends Censoring Bird Flu Papers

  
  Slashdot — Authority: 512
  Morty writes "The National Science Advisory Board for Biosecurity (NSABB) has recommended that details of two research papers involving Avian Flu not be published because of security concerns. At least one of the research groups says that their work should be logically reproducible. The NSABBs censorship ...
  15 hours ago

• AvidBiotics Sees New Angle for Personalized Medicine in Antibiotics

  
  Xconomy — Authority: 643
  Luke Timmerman When you hear about personalized medicine, you might think first of the applications for cancer treatment, or maybe cystic fibrosis . But Dave Martin, the former head of R&D at Genentech, is thinking about personalized medicine in a whole new context—for antibiotics. This concept, at South ...
  16 hours ago

• Vertex’s Big Day Felt Like Moon Landing, Seattle Researcher Says

  
  Xconomy — Authority: 643
  Luke Timmerman Bonnie Ramsey said three years ago that a cystic fibrosis drug from Vertex Pharmaceuticals was a huge medical advance in the making, and would end up being an achievement on par with putting a man on the moon , at least for her patients. Yesterday, she says, was the day it truly felt like she was ...
  16 hours ago

• Vertex Hep C Sales Growth Nears End

  
  TheStreet.com — Authority: 594
  CAMBRIDGE, Mass. (TheStreet) --Vertex Pharmaceuticals fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch. Current consensus estimate for fourth-quarter 2011 Incivek sales is $483 ...
  1 day ago

• Optimer, Following Pfizer’s Playbook, Has Big Plans for Antibiotic

  
  Xconomy — Authority: 643
  Luke Timmerman Pfizer was where Pedro Lichtinger learned about pharmaceutical marketing from people who did some amazing things. For starters, New York-based Pfizer turned an old-school antifungal medicine into a $1.6 billion cash cow. Now as the CEO of San Diego-based Optimer Pharmaceuticals (NASDAQ: OPTR ) ...
  1 day ago

• UCSD Researchers Create Artificial Cell Membrane

  
  Slashdot — Authority: 512
  cylonlover writes with an excerpt from a Gizmag article: "The cell membrane is one of the most important components of a cell because it separates the interior from the environment and controls the movement of substances in and out of the cell. In a move that brings mankind another step closer to being able to create ...
  1 day ago

• Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances

  
  TheStreet.com — Authority: 594
  SEATTLE (TheStreet) -- Cell Therapeutics withdrew its U.S. approval application for the experimental lymphoma pixantrone due to unresolved and undisclosed "communications" with the U.S. Food and Drug Administration, the company said. The surprise announcement from Cell Therapeutics means next Thursdays advisory ...
  2 days ago

• Never Back Smug: A Lesson for Life Sciences From Newt Gingrich

  
  Xconomy — Authority: 643
  Luke Timmerman Newt Gingrich comes across on TV as someone who radiates smugness. It’s that sense that he’s not just confident in his own abilities, but extremely satisfied with his talents and his utter superiority over mere mortals like you and me. I’m no political pundit, nor a psychologist, so I’ll ...
  2 days ago

• Biotage Releases New Catalog and Technical Guide for Sample Preparation and Evaporation

  
  Your Story — Authority: 489
  Biotage® introduced their 2012 catalog of analytical sample preparation products for chemistry professionals. Uppsala, Sweden, January 28, 2012 — Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced their 2012 catalog of analytical sample ...
  4 days ago

• 2012 Venture Outlook: Some Bright Spots and Some Gloom

  
  Xconomy — Authority: 643
  Bruce V. Bigelow It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital. Today he’ll make a similar presentation to the New Jersey Technology Council. Next week,  John ...
  5 days ago

• Cancer Institute Sues Biotech Company for More than $1 Billion Charging IP Theft

  
  Patent Baristas — Authority: 89
  A nonprofit cancer research institute has sued biotechnology company Agios and one of its cofounders for more than $1 billion, alleging they took intellectual property developed at the institute and used it to start a for-profit business. The Leonard and Madlyn Abramson Family Cancer Research Institute, part of the ...
  5 days ago

• Biotech Stock Mailbag: Vival, Hep C Drugs

  
  TheStreet.com — Authority: 594
  BOSTON (TheStreet) --Before I get to your emails and tweets, I want to remind everyone to submit your entries to my FDA Drug Approval Contest. Later today, the FDA is expected to announce its approval decision for Amylin Pharmaceuticals diabetes drug Bydureon. This will be followed by 16 more drug approval decisions ...
  5 days ago

• Stocks to Watch: P&G, Ford, Starbucks

  
  TheStreet.com — Authority: 594
  NEW YORK (TheStreet) -- Procter & Gamble, the consumer products giant, reported core profit for the fiscal second quarter of $1.10 a share on sales of $22.14 billion. Analysts expected it to post earnings of $1.08 a share on revenue of $22.19 billion. Net earnings were 57 cents a share. A year ago, P&G; ...
  5 days ago

• OncoGenex Stays in Prostate Cancer Fray, After J&J, Medivation

  
  Xconomy — Authority: 643
  Luke Timmerman Prostate cancer was once a backwater for innovation, but suddenly it’s become one of the most competitive battlegrounds in all of biotech. And one of the darkhorses in this race, Bothell, WA and Vancouver, BC-based OncoGenex Pharmaceuticals, is getting ready to show next week whether it has another ...
  5 days ago

• Why Biogen Idec Got Out of the Corporate VC Business

  
  Xconomy — Authority: 643
  Luke Timmerman Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French. The concept was unorthodox 25 years ago, yet over time, most every Big Pharma company has become an active ...
  5 days ago

• Breakthrough in diagnosing genetic mitochondrial disease and others

  
  Innovation Toronto — Authority: 127
  They found about 25 per cent of cases could be diagnosed straight awayA GROUP of scientists says a breakthrough in gene technology offers fresh hope to people suffering from some potentially fatal genetic conditions. The team based at the Murdoch Children’s Research Institute in Melbourne and the Broad Institute in ...
  5 days ago

• Theraclone, VLST Founders Form New Antibody Startup, V-Gene

  
  Xconomy — Authority: 643
  Luke Timmerman Two of the scientific founders of a couple of Seattle’s best-funded biotech startups have come together in a new company that aims to create a valuable antibody drug candidates while burning through the least amount of venture capital possible. The new Seattle-based company, called V-Gene, is ...
  6 days ago

• Affymax Prepares to Mount First Challenge to Amgen Anemia Drug Monopoly

  
  Xconomy — Authority: 643
  Luke Timmerman Affymax shocked the world when an FDA advisory committee recommended last month that its anemia drug was good enough to earn a spot on the U.S. market. Now the Palo Alto, CA-based company (NASDAQ: AFFY ) is making all sorts of moves behind the scenes that will determine how big a bite it will ...
  1 week ago

• Patent Agent - Small Corporation - San Diego, Calif.

  
  Patent Law Jobs by Patently-O — Authority: 114
  Verenium Corporation , a pioneer and recognized leader in the development and commercialization of high-performance enzymes for use in industrial processes, is seeking a Patent Agent. Are you an IP professional seeking a new role in a cutting edge, fast-paced green technology company? Is getting involved in the ...
  1 week ago

• Human stem cell therapy works in blind patients in first trial

  
  Innovation Toronto — Authority: 127
  The breakthrough holds out the hope of a cure in the future for age-related macular degeneration Scientists have improved the sight of two people who were almost blind by injecting their eyes with stem cells from embryos. The two women, both registered as blind, saw their vision improve in a matter of weeks after ...
  1 week ago

Comments about biotech